Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | FGF1 | P05230 | 2/20 | 0.35 |
| ▸ | FGF2 | P09038 | 2/20 | 0.35 |
| ▸ | VEGFA | P15692 | 2/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.35 |
| ▸ | SELP | P16109 | 6/20 | 0.33 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.33 |
| ▸ | CDC25B | P30305 | 5/20 | 0.33 |
| ▸ | SELE | P16581 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15965619 | 0.87 | TYMP (0.40) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL15952895 | 0.87 | NT5E (0.41) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL15952898 | 0.87 | NT5E (0.41) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL15965621 | 0.85 | LGALS3 (0.45) | FGF1FGF2VEGFAHPSESELP | |
| SCHEMBL13855489 | 0.80 | NT5E (0.44) | NT5ESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL13298919 | 0.79 | NT5E (0.46) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL15965629 | 0.78 | POLB (0.41) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL15965618 | 0.77 | POLB (0.42) | FGF2 | |
| SCHEMBL4402915 | 0.76 | FGF1 (0.39) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL4402910 | 0.75 | FGF2 (0.41) | NT5EFGF1FGF2VEGFAHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GLYCOM A/S (DK) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GNE, OGT, GALE | NT5E 206/4885FGF1 3824/4885FGF2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.